Mibg (I-123) Curiumpharma

Iobenguane Sulfate I-123, the active ingredient in Mibg (I-123) Curiumpharma, is a radiopharmaceutical presented as a solution for injection for intravenous use. It enables diagnostic imaging of adrenergic tissues, supporting detection of pheochromocytoma, neuroblastoma and assessment of cardiac sympathetic innervation.

GNH USA supplies Mibg (I-123) Curiumpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, nuclear medicine clinics and research institutions worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics through its global distribution network.

Mibg (I-123) Curiumpharma is used in nuclear medicine imaging of catecholamine‑producing tumors and cardiac sympathetic pathways.

- Pheochromocytoma: provides high‑resolution scintigraphic images to locate catecholamine‑secreting adrenal tumors. - Neuroblastoma: enables detection and staging of sympathetic‑origin neuroblastoma lesions in pediatric patients. - Cardiac sympathetic innervation assessment: visualizes myocardial sympathetic nerve distribution to evaluate heart failure or arrhythmia risk.

Adverse reactions to Mibg (I-123) Curiumpharma are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Mild nausea - Transient flushing